

Dysport® (abobotulinumtoxinA)



When requesting Dysport® (abobotulinumtoxinA), the individual requiring treatment must be diagnosed with one of the following FDA-approved indications and meet the specific coverage guidelines and applicable safety criteria for the covered indications.

FDA-approved indications

- Cervical dystonia
- Upper limb spasticity
- Lower limb spasticity

Coverage Guidelines

For all approved indications, the individual meets all of the following criteria:

- Does not have infection at the proposed injection site
- Does not have a known hypersensitivity to any botulinum toxin product or excipients
- Is not allergic to cow's milk protein
- Is 2 years of age or older

Approval duration: 12 months

Dosing Recommendations

Cervical Dystonia- 500 units IM as a divided doses every 12 weeks or longer

Lower and upper limb spasticity in adults: every 12 weeks

Muscle (upper limb)	Recommended dose (total dose[# sites])
flexor carpi radialis, flexor carpi ulnaris, flexor digitorum profundus, and flexor carpi superficialis	100 to 200 units [1 or 2]
brachialis and biceps brachii	200 to 400 units [1 or 2]
brachioradialis	100 to 200 units [1 or 2]
pronator teres	100 to 200 units [1]
Muscle (lower limb)	
gastrocnemius (medial or lateral head)	100 to 150 units [1]
soleus	330 to 500 units [3]
tibialis posterior	200 to 300 units [2]
Flexor digitorum longus	130 to 200 units [1 or 2]
Flexor hallucis longus	70 to 200 units [1]

Lower Limb Spasticity (patients $\geq$ 2 years of age): every 12 weeks

Muscle	Recommended dose (total dose [# of sites])
gastrocnemius	6 to 9 units/kg [up to 4]
soleus	4 to 6 units/kg [up to 2]

References

1. Dysport® (abobotulinumtoxinA) [prescribing information]. Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc.: July 2016. Accessed June 19, 2018.
2. Dysport® (abobotulinumtoxinA). In: DRUGDEX system Micromedex. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. [Updated November 11, 2017: Accessed June 19, 2018]
3. Simpson, DN, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical, dystonia, adult spasticity, and headache. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016; 26 86(19):1818-1826.
4. Dysport® (abobotulinumtoxinA). In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health System Pharmacists. [Updated February 27, 2018; Accessed July 19, 2018].